Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia - the role of busulfan pharmacokinetics in determining outcome by Chandy, M. et al.
Conditioning regimens
Randomized trial of two different conditioning regimens for bone marrow
transplantation in thalassemia – the role of busulfan pharmacokinetics
in determining outcome
M Chandy1, P Balasubramanian1, SV Ramachandran1, V Mathews1, B George1, D Dennison2,
R Krishnamoorthy3 and A Srivastava1
1Department of Hematology, Christian Medical College, Vellore, India; 2Sultan Qaboos University Hospital, Muscat, Oman;
and 3INSERM, U458, Hospital Robert Debre, Paris, France
Summary:
In total, 94 patients with homozygous beta thalassemia
were randomized to two different conditioning regimens:
busulfan 600mg/m2þ cyclophosphamide 200mg/kg or
busulfan 16mg/kgþ cyclophosphamide 200mg/kg and
antilymphocyte globulin (47 in each group), for bone
marrow transplantation, to see whether increased myelo-
ablation or increased immunosuppression would reduce
rejection. Busulfan pharmacokinetics in determining out-
come was evaluated. There was no significant difference in
engraftment, graft-versus-host disease, rejection, and
overall and disease-free survival in the two groups.
Systemic exposure to busulfan was significantly higher
in the 600mg/m2 group, but in both groups there was a
wide interindividual variation in the busulfan kinetics. Six
patients rejected the graft, two in the busulfan 600mg
group and four in busulfan 16mg group (P¼ 0.677 CI
0.17, 0.07), but in five patients (pharmacokinetic
data not available in one patient) who rejected the
graft busulfan first dose trough level (Cmin-1) was below
150 ng/ml while it was above this level in the 66 of 68
patients with successful engraftment (Pp0.001). This
randomized trial shows that rejection is influenced by
busulfan levels and suggests that monitoring of busulfan
levels and dose adjustment based on first-dose kinetics
may reduce the risk of rejection.
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Bone marrow transplantation (BMT) is today an alter-
native to life-long chelation and transfusion for children
with thalassemia major. Lucarelli et al have shown that for
children who have no hepatomegaly or fibrosis in the liver
and have been adequately chelated (Class I), an event-free
survival (EFS) of 92% can be achieved with transplant-
ation, but for children who have been inadequately
managed before transplant with all three risk factors (Class
III), the transplant-related complications and rejection are
high and the EFS is only 60%.1,2 Rejection is a major
problem in BMT for thalassemia, with rates varying from
11 to 55% in different series of BMT for thalassemia.3,4
Busulfan (Bu) and cyclophosphamide (Cy) are the two
agents used most commonly for conditioning in BMT for
thalassemia and of these two, Bu is considered to be the
main agent for myeloablation. Systemic exposure to Bu
may be a critical determinant of the degree of myeloabla-
tion achieved and we and others have reported a significant
interindividual variation in busulfan kinetics in patients
conditioned with Bu and Cy.5,6 It is also known that the
clearance of busulfan in children is higher than that in
adults and that for a given dose, the area under the curve is
lower for children than in adults. Vassal et al7 have shown
that children need to be given a dose of 600mg/m2 in order
to achieve a systemic exposure to Bu similar to adults given
16mg/kg. A child, whose body surface area is 0.5m2, may
therefore receive as much as 28mg/kg of Bu.
Storb et al8 have shown that it is possible to reduce
rejection in allogeneic BMT for severe aplastic anemia by
the addition of ALG to the conditioning regime of Cy
200mg/m2.
We therefore decided to evaluate in a randomized
manner whether increased systemic exposure to Bu with
600mg/m2 and consequently more effective myeloablation
or increased immunosuppression with antilymphocyte
globulin (ALG) combined with the standard dose of
16mg/kg of Bu would reduce rejection in patients receiving
an allogeneic BMT for thalassemia. In both groups, Bu
pharmacokinetics was determined to evaluate its effect on
outcome.
Patients and methods
Patients with an HLA six antigen serologically identical
donor with transfusion-dependent beta thalassemia major
were considered for allogeneic BMT at the Christian
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Medical College Hospital, Vellore and enrolled in the
study, which was conducted from January 1994 to
December 2002. Ethical clearance was obtained from the
institutional review board and informed consent was
obtained from the parents of all children entered on this
study.
Data analysis was performed in December 2004.
Conditioning
Patients were randomized using a computer generated
randomization list, to receive one of the following
conditioning regimens. Assuming a 10% difference in
rejection between the two groups the sample size would
be 148 in each arm.
1. REGIMEN A [Bu600]  busulfan 600mg/m2 given as
four divided doses over 4 days and cyclophosphamide
200mg/kg given over 4 days (50mg/kg/day i.v over 1 h).
2. REGIMEN B [Bu16]  busulfan 16mg/kg as 1mg/kg/
dose four times daily 4 days, cyclophosphamide
200mg/kg given over 4 days (50mg/kg/day i.v over
1 h) and ALG (Pasteur Merieux) 30mg/kg/day for 3
days.
Details regarding pre-transplant evaluation, prevention
of hemorrhagic cystitis, infection control policies, growth
factor use, graft-versus-host disease (GVHD) prophylaxis,
bone marrow harvest procedures and documentation of
chimerism have been reported earlier.9
The Glucksberg scale was used to grade acute GVHD10
and regimen-related toxicity was graded according to
Bearman’s11 criteria. Hepatic veno-occlusive was diagnosed
according to Baltimore criteria.12
Bu levels and pharmacokinetic analysis
The first dose of busulphan was given at 6 am to all
patients. All doses were given to patients on an empty
stomach. Blood samples (3–5ml) were taken from a central
venous catheter into glass tubes containing 150 IU heparin.
They were collected immediately before starting the drug
and at 0.5, 1, 1.5, 2, 4 and 6 h after the first, second and
13th doses. Samples were immediately refrigerated and
centrifuged within 1.5–3 h of collection and stored at 801C
until analysis. Plasma levels of Bu were measured after dose
1, 2, 6 and 13 using a newly developed HPLC method13 that
was validated with the previously reported GC-MS
method14 and showed significant correlation. Pharmaco-
kinetic parameters were analyzed using the TOPFIT
program.15 Parameters like elimination half-life (T1/2),
elimination rate constant (Kel), and AUC were estimated
directly from the data using noncompartmental analysis.
T1/2 was determined from the linear portions of the log
plasma AUC curves. All the other parameters were derived.
The mean concentration at steady state (Css) was calculated
from the following formulae:
Expected Css¼AUC0-a of 1st dose/dosing interval, that
is, 6 h.
Observed Css¼AUC0-6 h of the 13th dose/dosing
interval.
Clearance (Cl/F) was calculated as the ratio of dose to
AUC. Vd/F (in l/kg) was calculated as the ratio of Cl/F to
Kel. The minimum concentration (Cmin) was the trough
level of Bu before each dose. Mean residual value (MRV)
was calculated as the mean of all trough levels from dose 2
to dose 16. Maximum concentration (Cmax) was the peak
value of Bu after the first and 13th doses.
Statistical analysis
The Mann–Whitney U-test was used to compare between
the two groups using the statistical program SPSS version
11.0. Probabilities of disease-free survival (DFS) and
overall survival (OS) following transplant were estimated
by the Kaplan–Meier method and the significance was
assessed by log-rank test. Since interim analysis showed no
statistical difference in rejection between the two groups
and a relationship with busulfan pharmacokinetics inde-
pendent of the regimen, further recruitment was stopped.
Results
Table 1 (patient characteristics) shows that there was no
significant difference between the two groups in relation to
sex, age and Lucarelli class. The liver size, degree of hepatic
fibrosis, splenectomy status, serum ferritin levels and
positivity for viral markers was also not different in the
two groups. The donor age ranged from 2 to 42 years with
67% of the donors being heterozygous for beta thalasse-
mia. There was no significant difference in donor char-
acteristics between the two groups. In total, 26% of the
transplants were major group mis-matched. There was no
difference between the two groups in relation to engraft-
ment: time to ANC4500/mm3 was 14.5 days in the Bu 600
group and 16 days in the Bu 16 group and time to reach an
unsupported platelet count of 20 000/mm3 was 24.2 days in
the Bu 600 group and 26.3 days in the Bu 16 group. There
was no significant difference in the number of days in
hospital and in the incidence or severity of acute and
chronic GVHD in the two groups (acute GVHD 50%, with
20% being grade III/IV in both groups).
Table 1 Clinical details of patients
Bu 600/Cy
200 (n¼ 47)
Bu 16/Cy
200/ALG (n¼ 47)
P-value
n (%) n (%)
Age (years)
Mean7s.d. 6.74 3.31 7.55 2.97 0.516
Sex
Males 31 (66) 30 (64) 1.000
Females 16 (34) 17 (36)
Risk classification
Class II 21 (45) 22 (47) 1.000
Class III 25 (53) 25 (53)
Class II or III 1 (2) — —
Serum ferritin (ng/ml)
Mean7s.d. 3881.55 2042.24 3600.96 1659.10 0.680
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The differences in regimen-related toxicity in the two
groups is illustrated in Table 2. There was an increase in the
incidence of hepatic veno-occlusive disease in the 16mg
group when the Baltimore criteria were used, but this was
not statistically significant (P¼ 0.45). There was a statisti-
cally significant increase in the incidence of GI hemorrhage
in the group receiving 600mg/m2 of busulfan (P¼ 0.038).
Independent of the two groups there was a higher incidence
of bleeding in patients with higher busulfan levels (MRV
meanþ s.d. (ng/ml) 3227142 in patients with bleeding vs
255791 in those with no bleeding (P¼ 0.006). In Table 3,
the overall outcome and outcome in relation to Lucarelli
class is illustrated; again, there was no significant difference
between the two groups. In nine patients the mortality was
due to infections: cytomegalovirus – 3, viral pneumonia – 2,
bacterial sepsis – 3 and fungal pneumonia – 1. The
miscellaneous causes included intracranial hemorrhage –
2, cardiac tamponade – 1, hemorrhagic cystitis – 2,
myocarditis – 1 and graft failure – 2. Analysis of
engraftment in relation to growth factor use was not
different in the two groups.
Data on Bu pharmacokinetics are given in Table 4. There
were problems with sample collection and processing in 11
patients in the Bu 600 group and in one patient in the Bu 16
group. There were significantly higher MRV, Cmax, Cmin,
Tmax, Css and AUC in the Bu 600mg group than in the
16mg group. There was a marginal increase in clearance in
the Bu16 group (P¼ 0.05). However, there was a significant
inter-individual variation in both the groups with the AUC
ranging from 2796 to 8899 ng/h/ml in the Bu 600 group and
1876–5757 ng/h/ml in the Bu 16 group. This wide range was
also seen in Cmax, Cmin, MRV and Css, confirming the
variability between individuals with regard to all indicators
of Bu metabolism. In Table 5, the risk of VOD in relation
to Bu levels in both groups is shown. Patients with higher
clearance and lower Cmax, Css, Cmin and MRV had a
significantly higher incidence of VOD.
Four patients rejected the graft in the Bu 16mg group
while two patients rejected it in the Bu 600mg group, but
this was not statistically significant. However, as illustrated
in Table 6, there was a significant correlation between the
risk of rejection and the Bu pharmacokinetics. In five of the
six patients (for whom pharmacokinetic data is available)
who rejected the graft, the Cmin was below 150 ng/ml, while
all except two of the 68 evaluable patients with a Cmin
greater than 150 ng/ml did not reject the graft (Po0.001)
and this is illustrated in Figure 1. The Css, which is a
reflection of the AUC, was also lower in the group that
rejected the graft (476 vs 651.9 ng/ml), but this did not
reach statistical significance and the same is true for the
Cmax (844 vs 1108 ng/ml).
Discussion
In the first allogeneic transplant carried out for thalasse-
mia, Thomas et al in Seattle used a single dose of Bu
5mg/kg i.v. and 200mg of Cy for conditioning and the
patient still has a stable graft.16 Subsequently, Lucarelli
et al17 have evaluated different doses of Bu (14–16mg/kg)
and Cy 120–200mg/kg as conditioning for BMT in thalas-
semia. In children with Class I between 1983 and 1994,
conditioning consisted of Bu orally three times daily for 4
days (total dose, 14mg/kg body weight), followed by intra-
venous Cy once daily for 4 days (total dose, 200mg/kg),
with most patients receiving cyclosporine alone as GVHD
Table 2 Data on regimen-related toxicity
Bu 600/Cy
200 (n¼ 47)
Bu 16/Cy
200/ALG (n¼ 47)
P-value
n (%) n (%)
Stomatitis – evaluable 45/46 (96) 41/47 (87) 0.053
Grade I and II 16 (36) 26 (63)
Grade III–IV 29 (64) 15 (37)
Gastrointestinal
Grade I–II 4 (9) 6 (13) 0.526
GI Hemorrhage 31 (66) 20 (43) 0.038
Bladder (hemorrhagic cystitis)
Grade I and II 4 (8) 11 (23) 0.035
Grade III–IV 3 (6) 3 (6)
Hepatic
Grade I and II 31 (66) 27 (57) 0.662
Grade III 2 (4) 3 (6)
Central nervous system
Grade III 1 (2) 1 (2) 1.000
Pulmonary
Grade III 1 (2) 3 (6) 0.617
Veno-occlusive disease of liver
Seattle criteria 27 (57) 27 (57) 1.000
Baltimore criteria 8 (17) 12 (26) 0.450
Table 3 Analysis of outcome in relation to busulfan dose
Bu 600/Cy
200
Bu 16/Cy
200/ALG
P-value
n (%) n (%)
Overall survival 32 (68) 34 (47) 0.822
Disease-free survival 32 (68) 30 (64) 0.828
Follow-up (months) median 63 1–124 52 1–124 0.376
Rejection 2 (4) 4 (9) 0.677**
Mortality 15 (32) 13 (28) 0.652*
Outcome by class
Class II n¼ 21 n¼ 22
Overall survival 17 (81) 19 (86) 0.698
Disease-free survival 17 (81) 19 (86) 0.698
Rejection — — — — —
Mortality 4 (19) 3 (14) 0.631
Class III n¼ 26 n¼ 25
Overall survival 15 (58) 15 (60) 1.000
Disease-free survival 15 (58) 11 (44) 0.406
Rejection 2 (10) 4 (22) 0.302
Mortality 9 (35) 10 (40) 0.691
95% CI: *0.08, 0.16; **0.17, 0.07.
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prophylaxis. The OS, EFS and mortality were 96, 90 and
4%, respectively. Using a similar protocol in Class II
patients, the OS, EFS and mortality were 86, 83 and 14%,
with 3% rejection. However, in 55 patients with Class III
treated with the same protocol, the mortality was 42%;
hence, from 1989, 165 patients were treated with 14–16mg
of Bu and 120–160mg of Cy with OS, EFS, rejection and
nonrejection mortality of 79, 58, 30 and 18%. The
reduction in mortality was at the price of increased
rejection.17 Ball et al4 from the Netherlands report a
rejection rate of 55% in 21 transplants for thalassemia
using Bu/Cy conditioning with or without ATG. In
Taiwan, DFS was only 44% with graft rejection being the
major cause for failure.18 However, data from Hong Kong
show results similar to those achieved in Pesaro,5 while
Lawson et al19 from UK, using Bu14 and Cy200 in 55
consecutive transplants for thalassemia, had an 81%
thalassemia-free survival and 13.2% rejection. In this
study, we have been able to achieve an overall and DFS
of 84% in 43 patients who were in Lucarelli class II with no
rejection, and a mortality of 16.3% that is similar to data
from Pesaro. The DFS of 51% in the Class III patients in
this study is also close to the 58% figure of Lucarelli, but
the mortality of 37 and 30% in the two studies remains
unacceptably high. Alternative approaches to reduce
Table 4 Busulfan pharmacokinetics
Bu 600/Cy 200 (n¼ 36) Bu 16/Cy 200/ALG (n¼ 46) P-value
Mean s.d. Mean s.d.
Mean residual value (ng/ml) 343.18 126.87 234.4 87.36 o0.001
Cmax (ng/ml) 1318 416 902 325 o0.001
Cmin (ng/ml) 282.44 127.75 198.96 65.6 0.002
Tmax (h) 1.53 1.03 1.33 0.78 0.321
AUC (ng h/ml) 5074.94 1639.07 3119.15 837.43 o0.001
T1/2 (/h) 2.31 0.88 2.46 0.87 0.486
Cl (l/h/kg) 0.31 0.07 0.35 0.08 0.029
Css (ng/ml) 845.83 273.12 529.41 148.41 o0.001
Cmax, Cmin, Tmax, AUC, T1/2, Cl, Css are for dose 1.
Pharmacokinetic data were not available in 11 patients in Regimen A and one patient in Regimen B.
Table 5 HVOD (Baltimore Criteria) in relation to busulfan pharmacokinetics (both groups combined)
With HVOD No HVOD P-value
n Mean s.d. n Mean s.d.
Css-1 (ng/ml) 20 577.0 181.53 62 697.79 279.85 0.030
Cmin-1 (ng/ml) 20 204.7 64.81 62 245.58 114.55 0.051
Cl/F-1 (l/h/kg) 20 0.35 0.06 62 0.33 0.08 0.001
Cmax-1 (ng/ml) 20 911.4 289.02 63 1143.43 442.40 0.009
AUC-1(ng h/ml) 20 3461.9 1089.7 62 4144.2 1685.2 0.040
MRV (ng/ml) 20 247.9 79.55 66 294.59 27.77 0.055
Table 6 Graft rejection in relation to busulfan pharmacokinetics (both groups combined)
Rejection (n¼ 5) No rejection (n¼ 68) P-value
Mean s.d. Mean s.d.
Cmin-1 (ng/ml) 113.8 20.3 240.4 103.1 o0.001
Css-1 (ng/ml) 475.6 180.5 678.6 251.9 0.049
Cl/F-1 (l/h/kg) 0.41 0.09 0.33 0.07 0.081
Cmax-1 (ng/ml) 844.0 301.1 1138.6 420.1 0.066
AUC-1 (ng h/ml) 2854.4 1082.1 4032.7 1514.9 0.052
Complete pharmacokinetics data were evaluable in 73 cases that were evaluable for rejection.
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Figure 1 Probability of graft rejection depending on busulfan Cmin-1.
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toxicity and rejection by using a nonmyeloablative regime
have been tried, but in one study using fludarabine and TBI
all six patients with sickle cell anemia and one with
thalassemia rejected, suggesting that this approach would
not work in children who have been multiply transfused.20
The more recent approach that the Pesaro group has taken
using hydroxyurea and azathioprine appears to be promis-
ing and the report of improvement in outcome of sickle
cell anemia patients who were on hydroxyurea prior to
transplant supports this concept for conditioning.21,22
There are no randomized trials on different conditioning
approaches for BMT in thalassemia published in the
English language literature. The basic conditioning regimen
that we decided to use was Bu at 16mg/kg: we did not want
to reduce the Bu dose to 14mg/kg since these were multiply
transfused children with an increased risk of rejection, and
we kept the dose of Cy at 200mg/kg and added ALG. The
addition of ALG was based on the data from Seattle, which
showed that the addition of ALG to Cy 200mg/m2 for
multiply transfused patients with aplastic anemia reduced
the rejection rate.23 With this regimen (B), no patient in
Lucarelli Class II rejected the graft and the mortality was
low (16.3%).
The first hypothesis that was tested in this study was to
see whether optimizing the systemic exposure to Bu by
dosing at 600mg/m2 would reduce the rejection rate
without increasing toxicity. Vassal and co-workers8,24 first
studied the disposition of Bu in children below 3 years and
noted a higher clearance, particularly in children with
lysosomal storage disorders, and suggest that 600mg/m2
may be a more appropriate dose for children. Hassan et al25
demonstrated that the difference in clearance of Bu
between children and adults was not significant when
normalized to body surface areas, which is in agreement
with the data of Vassal and co-workers.8,24 In two clinical
trials of BMT in children with 600 or 650mg/m2 of Bu26,27
using the Bu/Cy regimen, there was no significant increase
in HVOD.
In this study we have shown for the first time, in children
with thalassemia, that giving Bu at 600mg/m2 is feasible
with only two rejections (4.25%) and the only toxicity
observed was an increase in GI hemorrhage. This study
also shows that Bu at 600mg/m2 is equivalent to the
standard conditioning of Bu16/Cy200 with ALG. The
design of this study does not allow us to determine the
independent contribution of ALG in reducing rejection
since we did not have a group that received 16mg/kg
Buþ 200mg/kg Cy without ALG.
However, we did find significant differences in rejection
in relation to Bu kinetic parameters irrespective of whether
the patient received 16m/kg or 600mg/m2 of Bu. This
suggests that systemic exposure to Bu is an important
determinant of the efficacy of myeloablation/immuno-
suppression and therefore transplant outcome in relation
to rejection. Since there was no reduction of rejection in the
600mg/m2 group despite the much greater dose in younger
children, the effect of interindividual differences in phar-
macokinetics is extremely significant. Slattery et al28 also
showed the wide variability in plasma concentrations in
patients receiving oral Bu, and that low concentrations
predispose to graft rejection while high levels increase the
risk of toxicity. They subsequently showed in a study of
BMT for CML that the Bu Css median 917 ng/ml was the
only statistically significant determinant of relapse in
univariate or multivariate analysis.29 This group has also
reported that busulfan Css was the only statistically
significant predictor of rejection on univariate logistic
regression analysis, with the risk of rejection decreasing
with an increase in busulfan Css in a multivariate Cox time-
to-rejection analysis in children undergoing BMT for
diseases other than thalassemia.30 They found that an
average concentration of Bu at steady state of at least
200 ng/ml was needed to avoid rejection of a matched-
sibling graft.28
In this study, in 66 of 68 patients with successful
engraftment, the Cmin-1 was greater than 150 ng/ml while
in five of the six patients who rejected the graft, the Cmin-1
was below 150 ng/ml. These data are not in accordance with
the previously published data by Pawlowska et al31 from
the Pesaro group who did not find any association with Bu
kinetics and rejection or mortality. However in their study,
which is the only other large series other than this report,
that has looked at the pharmacokinetics of Bu in patients
with thalassemia, the dose of Bu was 14–16mg/kg and the
Cy dose varied from 120 to 200mg/kg.
Pawlowska et al31 also did not find any correlation
between Bu levels and toxicity. Grochow et al noted the
wide inter-individual variation in Bu kinetics and the
relationship to VOD, with all six patients who developed
VOD in their series having an AUC that was greater than
the mean.32 Others have also subsequently noted this
association between VOD and Bu kinetics.33,34 Ljungman
et al35 reported a correlation between the minimum level of
BU and the severity of alopecia following transplantation,
but do not mention whether the AUC or Cmax was related.
Grochow et al32 found that in 27 patients with high AUCs
(41500mmolmin/l) after the first dose, when the fifth
through 16th doses of Bu were decreased, the incidence of
VOD was only 18% while those patients with high AUCs
who did not receive dose adjustments had a 75% incidence
of VOD. The data from this study, however, differ from
that published so far in that we found a significantly higher
clearance in patients who developed VOD with lower AUC,
Cmax, Cmin and MRV.
6 Subsequently, we have found an
association between GSTM1 and clearance and speculate
that accelerated clearance produces VOD either by deple-
tion of glutathione or by increased production of a toxic
metabolite.36 There was an association between gastro-
intestinal bleeding and high Bu levels. Studies showing
inter-patient variability and relationship of toxicity, relapse
and rejection to Bu levels have led to monitoring of drug
levels and dose adjustment based on the kinetics of the first
dose administered. Bleyzac et al showed that this strategy
resulted in a dose reduction in 69%, increase in 27.6% and
no change in only 0.03%. They also showed that this
resulted in a reduction in graft failure, VOD and an
improvement in survival when compared to a control group
where no drug monitoring or dose adjustment was made.37
Demirer,38 however, reports that dose escalation of BU
based on targeted plasma levels did not improve the
outcome in patients with CML undergoing BMT. Dupuis
et al from Toronto found that a change from the initial Bu
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dose was required to achieve the target AUC in 34 courses
(87%). Most children 41 to 5 years required dose
increments, while most children 45 years required dose
reductions.39 Current data suggest that therapeutic drug
monitoring may improve outcome by ensuring adequate
systemic exposure and therefore reduced relapse, rejection
and regimen-related toxicity.40 However, the level of
different pharmacokinetic parameters of Bu to achieve this
result may depend on the disease for which transplantation
is being done and specific host and donor characteristics.
Intravenous busulfan may reduce the variability due to
differences in gastrointestinal absorption and first-pass
metabolism and have less VOD, but this needs to be
documented in a randomized trial for thalassemia.
This study shows that the systemic exposure to Bu is
important in reducing rejection and the best way to ensure
this would be by individualized dosing based on first dose
pharmacokinetics.
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